Report Id: SNS/HC/1070 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Radiopharmaceuticals Market Size was valued at USD 4.65 billion in 2021, and is expected to reach USD 9.4 billion by 2028, and grow at a CAGR of 9.2% over the forecast period 2022-2028. The effect of the worldwide COVID-19 pandemic has been exceptional and faltering, with encountering lower interest across all locales contrasted with pre-pandemic levels. In view of our investigation, the worldwide market development had shown a downfall of - 4.4% in 2021 when contrasted with the typical year-on-year development during 2022-2028. The unexpected ascent in CAGR is inferable from this market's interest and development, getting back to pre-pandemic levels once the pandemic is finished.
Atomic prescriptions are a gathering of drug sedates that contain radioactive isotopes. They are selective therapeutic plans with radioisotopes and are utilized in major clinical regions for analysis or treatment. Throughout the course of recent years, radiopharmaceutical treatments have arisen as perhaps the most effective procedures in different region, like nervous system science, cardiology, oncology, and others.
The market development is for the most part credited to the developing pervasiveness of ongoing illnesses. Besides, innovative headways empowering the utilization of radiopharmaceuticals to analyze and treat destructive cancers add to showcase development. Moreover, the market players zeroing in on different procedures, for example, new item dispatches and acquisitions are supposed to increment market income before long.
Radiopharmaceuticals Market Dynamics
Rising pervasiveness of sicknesses
Innovative work proficiencies
Developing venture for medical care offices
Moreover, upsurge in the public-private financing for target research exercises, rising mindfulness about the advantages of alpha radio immunotherapy based designated malignant growth treatment, rising geriatric populace base and rising item advancements and improvement attributable to mechanical progressions from one side of the planet to the other will broaden beneficial open doors for the market players in the gauge time of 2022 to 2028. Moreover, in drives to decrease the interest supply hole of mo-99 , increasing web infiltration rate, expansion in use of radioisotopes in the medical services industry, rising utilization of radio-pharmaceuticals in neurological applications and expanding per capitla use on medical care will additionally extend the market's development rate from here on out.
Then again, significant expense related with the innovative work proficiencies, restricted infrastructural offices, short half-existence of radiopharmaceuticals, high hardware costs and lack of mindfulness in the regressive economies are supposed to hinder market development. Additionally, absence of ideal repayment situation and innovation infiltration in the creating economies, clinic financial plan cuts particularly during the pandemic, and absence of reasonable foundation in low-and center pay nations are projected to challenge the market in the conjecture time of 2022-2028.
This radiopharmaceuticals market report gives subtleties of new ongoing turns of events, exchange guidelines, import-trade investigation, creation examination, esteem chain streamlining, portion of the overall industry, effect of homegrown and confined market players, examinations valuable open doors as far as arising income pockets, changes in market guidelines, vital market development investigation, market size, class market developments, application specialties and strength, thing supports, thing dispatches, geographic augmentations, mechanical progressions on the lookout.
IMPACT OF COVID-19 Analysis
Coronavirus Pandemic Hampered Market Revenue Due to Declining Diagnosis Procedures
The COVID-19 pandemic harmed the market in 2020. The issues like absence of labor force and staff, hazard of transmission of COVID-19, and the decrease in the imaging systems, for example, PET-CT SPECT methodology represented a test for the market development in 2020. The reduction in the strategies can be inferable from disturbance of supply chains, calculated difficulties, security precautionary measures reception, which isn't not difficult to keep up with by the focuses.
For example, as indicated by the study distributed by the Journal of Nuclear Medicine, in April 2020, there was a mean decrease of treatments by 45.0%. Focuses announced diminishes in radioiodine treatment for thyroid malignant growth and harmless illnesses by a normal of 47% and 63%, separately.
Complete and incomplete lockdowns in a large portion of the nations and significant limitations on air travel, the vehicle of radionuclides, and radiopharmaceuticals turned into the principal bottlenecks to the dispersion of items to medical clinics.
The market players saw a critical decrease in income produced during 2020. For example, Jubilant Pharmova Limited saw a reduction of 2.7% in its income from USD 1,249.6 million of every 2019 to USD 1,215.6 million out of 2020. Radiopharmaceuticals' income saw an abatement of 26.6% from USD 356.0 million of every 2019 to USD 261.4 million out of 2020.
Nonetheless, during Q3-04 2020, patient volumes began expanding as the guidelines forced by the public authority of different nations were loose. Subsequently, the resumption of administrations decidedly affected the interest for Radiopharmaceuticalsin 2021.
The Radiopharmaceuticals market in the U.S. is assessed at US$2.7 Billion in the year 2021. The nation presently represents a 48% offer in the worldwide market. China, the world's second-biggest economy, is conjecture to arrive at an expected market size of US$545.7 Million in the year 2026 following a CAGR of 11.3% through the examination period.
Among the other imperative geographic business sectors are Japan and Canada, each figure to develop at 6.7% and 6.5% individually over the examination period. Inside Europe, Germany is estimated to develop at around 7.6% CAGR while Rest of the European market (as characterized in the review) will arrive at US$591.5 Million toward the finish of the examination time frame.
KEY MARKET SEGMENTS:
By Radioisotope Type
Hospital & Clinics
Ambulatory Surgical Centers
Cancer Research Institute
North America created an income of USD 2.57 billion of 2020 and is expected to proceed with its predominance during the gauge time frame. The quick reception of productive atomic imaging innovations combined with the rising use of mechanically progressed and proficient remedial radiopharmaceuticals across the district are supposed to drive market development. Other than this, the rising pervasiveness of different diseases and other ongoing issues is supposed to fuel the development of the market in North America during the conjectured time frame.
Europe is projected to observe the second-most elevated development in the market because of the reception of cutting-edge radiopharmaceuticals and ongoing item dispatches by the central participants. Plus, the procurement and consolidations by market players of this district are additionally powering provincial development.
Then again, the Asia Pacific is supposed to grow at a significant CAGR during the estimated time frame. Because of the rising dispensable earnings across the area, there is more prominent mindfulness concerning imaging diagnostics and their use in the compelling determination and the board of different sicknesses. Expanding procedural volumes of atomic imaging because of the expanded commonness of persistent issues in the significant nations like India, China, and Japan are further pushing the market development in the Asia Pacific locale.
The Rest of the world, which integrates the Latin America and the Middle East and Africa areas, should notice moderate improvement on account of extending clinical benefits utilization and rising thoughtfulness regarding useful diagnostics and therapeutics for the organization of fundamental thought issues.
Some of the major key players of Radiopharmaceuticals Market are as follows: GE healthcare, Jubilant life sciences, Curium, JSC isotopes, Novartis AG, Bracco diagnostic, Cardinalhealth, Norgine B.V, Siemens healthiness, Curium, Lantheus Medical imaging, Australian Nuclear Science and Technology.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 4.65 Billion|
|Market Size by 2028||US$ 9.4 Billion|
|CAGR||CAGR of 9.2% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Radioisotope Type (Technetium-99, Fluorine-18, Iodine-131, Leutetium-177, Yttrium-90, Gallium-68, Gallium-67, Rubidium-82, Iodine-123, Iodine-125, Indium-111, Others)
• By Source (Cyclotrons, Nuclear Reactors)
• By( application(Neurology, Cardiology, Oncology, Gastroenterology, Nephrology, Neuroendocrinology, others )
• By end-user (Hospital & Clinics, Diagostics Center, Ambulatory Surgical Centers, Cancer Research Institute, Others )
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||GE healthcare, Jubilant life sciences, Curium, JSC isotopes, Novartis AG, Bracco diagnostic, Cardinalhealth, Norgine B.V, Siemens healthiness, Curium, Lantheus Medical imaging, Australian Nuclear Science and Technology.|
|DRIVERS||• Rising pervasiveness of sicknesses
• Innovative work proficiencies
•Developing venture for medical care offices
Frequently Asked Questions (FAQ) :
Radiopharmaceuticals are often used as biomarkers in molecular thinking. With nuclear radiopharmaceuticals, there are also various diagnostic tests.
Yes, a data validation process is followed in this report.
Radiopharmaceuticals are substances that emit radiation or nuclear drugs used in the medical field for diagnostic and therapeutic purposes.
Radiopharmaceutical manufacturing rules are stringent, and adverse effects from radiopharmaceuticals can limit market expansion.
The market is expected to increase at a CAGR of 19.6%.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine-Russia War
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Radiopharmaceuticals Market Segmentation, by Radioisotope type
9. Radiopharmaceuticals Market Segmentation, by Source type
9.2 Nuclear Reactors
10. Radiopharmaceuticals Market Segmentation, by application
11. Radiopharmaceuticals Market Segmentation, by end-user
11.1Hospital & Clinics
11.2 Diagostics Center
11.3 Ambulatory Surgical Centers
11.4 Cancer Research Institute
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13. Company Profiles
13.1 Australian Nuclear Science and Technology
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 GE healthcare
13.3 Jubilant life sciences
13.4 Curium, JSC isotopes
13.5 Novartis AG
13.6 Bracco diagnostic
13.7 Norgine B.V
13.8 Siemens healthiness
13.10 Lantheus Medical imaging
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.
Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.